Lysosome-targeted octadecyl-rhodamine B-liposomes enhance lysosomal accumulation of glucocerebrosidase in Gauchers cells in vitro

Nanomedicine

Volumn 8, Issue 7, 2013, Pages 1055-1065

  Thekkedath, Ritesh ^a   Koshkaryev, Alexander ^a   Torchilin, Vladimir P ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

enzyme replacement therapy; glucocerebroside; liposomes; lysosomal targeting; rhodamine B; velaglucerase alfa; VPRIV

Indexed keywords

GLUCOSYLCERAMIDASE; LIPOSOME; RHODAMINE; VELAGLUCERASE ALFA;

ARTICLE; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONFOCAL LASER MICROSCOPY; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; FIBROBLAST; FLOW CYTOMETRY; GAUCHER DISEASE; IN VITRO STUDY; LYSOSOME; MACROPHAGE; MONOCYTE; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

EID: 84879624770     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.138     Document Type: Article

References (27)

1. Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 372(9645), 1263-1271 (2008).
2. Van Der Ploeg AT, Reuser AJ. Pompe's disease. Lancet 372(9646), 1342-1353 (2008).
3. Zarate YA, Hopkin RJ. Fabry's disease. Lancet 372(9647), 1427-1435 (2008).
4. Grabowski GA, Hopkin RJ. Enzyme therapy for lysosomal storage disease: principles, practice, and prospects. Ann. Rev. Genomics Hum. Genet. 4, 403-436 (2003). (Pubitemid 37392929)
5. Jmoudiak M, Futerman AH. Gaucher disease: pathological mechanisms and modern management. Br. J. Haematol. 129(2), 178-188 (2005). (Pubitemid 40562438)
6. Naito M, Takahashi K, Hojo H. An ultrastructural and experimental study on the development of tubular structures in the lysosomes of Gaucher cells. Lab. Invest. 58(5), 590-598 (1988).
7. Bussink AP, Van Eijk M, Renkema GH, Aerts JM, Boot RG. The biology of the Gaucher cell: the cradle of human chitinases. In: International Review of Cytology. Kwang WJ (Ed.). Academic Press, TN, USA, 71-128 (2006). (Pubitemid 44375087)
8. Piran S, Amato D. Gaucher disease: a systematic review and meta-analysis of bone complications and their response to treatment. J. Inherit. Metab. Dis. 33(3), 271-279 (2010).
9. Elstein D, Cohn GM, Wang N, Djordjevic M, Brutaru C, Zimran A. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease. Blood Cells Mol. Dis. 46(1), 119-123 (2011).
10. Lachmann RH. Enzyme replacement therapy for lysosomal storage diseases. Curr. Opin. Pediatr. 23(6), 588-593 (2011).
11. Connock M, Burls A, Frew E et al. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review. Health Technol. Assess. 10(24), iii-iv, ix-136(2006).
12. Gregoriadis G. Liposomes in the therapy of lysosomal storage diseases. Nature 275(5682), 695-696 (1978).
13. Gregoriadis D, Louis L, Neerunjun D. Comparative effect and fate of non-entrapped and liposome-entrapped neuraminidase injected into rats. Biochem. J. 140(2), 323-330 (1974).
14. Patel HM, Ryman BE. Alpha-mannosidase in zinc-deficient rats. Possibility of liposomal therapy in mannosidosis. Bioch. Soc. Trans. 2, 1014-1017 (1974).
15. Steger LD, Desnick RJ. Enzyme therapy. VI: comparative in vivo fates and effects on lysosomal integrity of enzyme entrapped in negatively and positively charged liposomes. Biochim. Biophys. Acta 464(3), 530-546 (1977).
16. Braidman IP, Gregoriadis G. Rapid partial-purification of placental glucocerebroside b-glucosidase and its entrapment in liposomes. Biochem. J. 164(2), 439-445 (1977). (Pubitemid 8105682)
17. Umezawa F, Eto Y, Tokoro T, Ito F, Maekawa, K. Enzyme replacement with liposomes containing beta-galactosidase from Charonia lumpas in murine globoid cell leukodystrophy (twitcher). Biochem. Biophys. Res. Commun. 127(2), 663-667 (1985). (Pubitemid 16217478)
18. Koshkaryev A, Thekkedath R, Pagano C, Meerovich I, Torchilin VP. Targeting of lysosomes by liposomes modified with octadecyl-rhodamine B. J. Drug Target 19(8), 606-614 (2011).
19. Newburg DS, Shea TB, Yatziv S, Raghavan SS, McCluer RH. Macrophages exposed in vitro to conduritol B epoxide resemble Gaucher cells. Exp. Mol. Pathol. 48, 317-323 (1988).
20. Das PK, Murray GJ, Gal AE, Barranger JA. Glucocerebrosidase deficiency and lysosomal storage of glucocerebroside induced in cultured macrophages. Exp. Cell. Res. 168(2), 463-474 (1987).
21. Yatziv S, Newburg DS, Livni N, Barfi G, Kolodny EH. Gaucher-like changes in human blood-derived macrophages induced by beta-glucocerebrosidase inhibition. J. Lab. Clin. Med. 111(4), 416-420 (1988).
22. Meerovich I, Koshkaryev A, Thekkedath R, Torchilin VP. Screening and optimization of ligand conjugates for lysosomal targeting. Bioconjug. Chem. 22(11), 2271-2282 (2011).
23. Daigneault M, Preston JA, Marriott HM, Whyte MK, Dockrell DH. The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS ONE 5(1), e8668 (2010).
24. Luzio JP, Pryor PR, Bright NA. Lysosomes: fusion and function. Nat. Rev. Mol. Cell Biol. 8(8), 622-632 (2007). (Pubitemid 47106614)
25. Huth U, Wieschollek A, Garini Y, Schubert R, Peschka-Suss R. Fourier transformed spectral bio-imaging for studying the intracellular fate of liposomes. Cytometry A 57(1), 10-21 (2004). (Pubitemid 38055710)
26. Schnyder A, Huwyler J. Drug transport to brain with targeted liposomes. NeuroRx 2(1), 99-107 (2005). (Pubitemid 40128030)
27. Sou K, Goins B, Oyajobi BO, Travi BL, Phillips WT. Bone marrow-targeted liposomal carriers. Expert Opin. Drug Deliv. 8(3), 317-328 (2011).